Bristol Myers Squibb Wins First CAR-T Therapy Approval in Multiple Myeloma

Bristol Myers Squibb Wins First CAR-T Therapy Approval in Multiple Myeloma The FDA has approved a Bristol Myers Squibb cell therapy made by engineering a patient’s immune cells to target a cancer protein called BCMA. The regulatory decision for Abecma in multiple myeloma gives BMS its second approved CAR-T therapy.